
The Google DeepMind spin-off plans to use the funds to advance its AI drug discovery programmes and move its first drug candidates towards clinical trials.
Isomorphic Labs said on Tuesday it
has raised $5 billion in a Series C funding round co-led by
Greenoaks and Sequoia Capital, as the Alphabet-backed
AI drug discovery company works to move its first drug
candidates into clinical trials.
The company, which was spun out of Google DeepMind in 2021,
declined to share its valuation. The funding comes about six
months after it raised $2.1 billion in a Series B round led by
Thrive Capital.
Here are more details:
* Andreessen Horowitz and other new investors joined the
round, while Alphabet made a significant investment and other
existing backers, including Thrive, MGX and GV, also
participated
* “This round enables us to accelerate our progress:
building foundational biology models, deepening our systemic
disease understanding, and driving our first therapeutic
programs towards clinical trials to deliver tangible impact for
patients,” Isomorphic founder and CEO Demis Hassabis said
* The company is developing its IsoDDE drug design engine,
which uses AI to design new drugs, predict their properties and
refine them before scientists decide on the candidates to make
and test
* Isomorphic said it has seen positive pre-clinical results
in internal oncology and immunology programs and with partners,
“setting the stage for clinical entry”
* The company lists Novartis, Eli Lilly and
Johnson & Johnson as its partners, according to its
website
Published on November 17, 2026